View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
November 17, 2011

Gilead and Tibotec to develop HIV medication

Gilead Sciences has entered into a licence agreement with Tibotec Pharmaceuticals to develop and market a single-tablet regimen comprising Prezista (darunavir), Emtriva (emtricitabine, GS7340) and cobicistat, a pharmacoenhancer.

Gilead Sciences has entered into a licence agreement with Tibotec Pharmaceuticals to develop and market a single-tablet regimen comprising Prezista (darunavir), Emtriva (emtricitabine, GS7340) and cobicistat, a pharmacoenhancer.

Under the agreement, Gilead will be responsible for the formulation, manufacturing, registration, distribution and commercialisation of the single-tablet regimen worldwide, while Tibotec will co-detail the single-tablet regimen in certain major markets.

Gilead Sciences chief scientific officer Norbert Bischofberger said that his is the first time the company is developing a protease inhibitor-containing single-tablet regimen, due to the small milligram size of GS 7340.

"We are pleased to once again be partnering with Tibotec to advance and simplify HIV treatment for patients," Bischofberger added.

Gilead plans to begin a Phase II study of GS 7340, an anti-HIV agent, in 2012.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena